Madrigal pharmaceuticals provides corporate update and reports 2021 third quarter financial results

Several abstracts with data from the open-label arm of the phase 3 maestro-nafld-1 study accepted for presentation at aasld's upcoming the liver meeting® 2021 several abstracts with data from the open-label arm of the phase 3 maestro-nafld-1 study accepted for presentation at aasld's upcoming the liver meeting® 2021
MDGL Ratings Summary
MDGL Quant Ranking